Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for D. Western Therapeutics Institute's Debt-to-Equity or its related term are showing as below:
TSE:4576'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.15 Med: 0.37 Max: 1.3
Current: 0.41
During the past 13 years, the highest Debt-to-Equity Ratio of D. Western Therapeutics Institute was 1.30. The lowest was 0.15. And the median was 0.37.
TSE:4576's Debt-to-Equity is ranked worse than 70.74% of 957
companies
in the Biotechnology industry
Industry Median: 0.16
vs TSE:4576: 0.41
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
D. Western Therapeutics Institute Debt-to-Equity Related Terms
D. Western Therapeutics Institute Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute Debt-to-Equity Chart
TSE:4576 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, D. Western Therapeutics Institute's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute (TSE:4576) has a Debt-to-Equity of 0.41 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on D. Western Therapeutics Institute and its competitors. This is 11% above median its historical median of 0.37. Over the past decade, D. Western Therapeutics Institute's Debt-to-Equity has ranged from 0.15 to 1.30. According to the industry distribution chart, D. Western Therapeutics Institute ranks #677 out of 957 companies in the Biotechnology industry, placing it in the top 70.7%.
Is D. Western Therapeutics Institute's Debt-to-Equity too high?
D. Western Therapeutics Institute's current Debt-to-Equity of 0.41 is 11% above median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 1.30. The Biotechnology industry median Debt-to-Equity is 0.16. D. Western Therapeutics Institute's value of 0.41 is 156.3% above this industry median. Based on the distribution chart, D. Western Therapeutics Institute ranks #677 out of 957 companies in the Biotechnology industry, which is below the industry midpoint. Overall, D. Western Therapeutics Institute has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #677 out of 957 companies for Debt-to-Equity. This places D. Western Therapeutics Institute in the lower half of its industry. The industry median Debt-to-Equity is 0.16. D. Western Therapeutics Institute's value of 0.41 is 156.3% above this benchmark. Historically, D. Western Therapeutics Institute's own Debt-to-Equity has ranged from 0.15 to 1.30 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 0.16, D. Western Therapeutics Institute has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. D. Western Therapeutics Institute's current Debt-to-Equity of 0.41 is 156.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on D. Western Therapeutics Institute and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. D. Western Therapeutics Institute's current Debt-to-Equity is 0.41, which is 11% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Significantly Overvalued. The stock's GF Value™ is 円44.54, compared to a current price of 円89.00 — trading 99.8% above its estimated fair value. The current Debt-to-Equity is 0.41, which is 11% above median its 10-year median of 0.37 and 156.3% above the Biotechnology industry median of 0.16. D. Western Therapeutics Institute's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current Debt-to-Equity is 0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of 円89.00 is trading 99.8% above its estimated GF Value™ of 円44.54.
GuruFocus considers D. Western Therapeutics Institute to be Significantly Overvalued.
Key valuation signals for TSE:4576:
Debt-to-Equity: 0.41 (11% above median its 10-year median of 0.37)
GF Value™: 円44.54 vs. price of 円89.00 (99.8% above fair value)
Industry Position: 156.3% above the Biotechnology median (#677 of 957)
No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
39GF Score
Get the complete analysis for TSE:4576
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4576 has been successfully added to your 
